CVS vs. DHR: Which Stock Is the Better Value Option?

27.06.25 17:40 Uhr

Werte in diesem Artikel
Aktien

58,50 EUR 0,41 EUR 0,71%

Indizes

PKT PKT

17.133,8 PKT 101,4 PKT 0,60%

3.031,5 PKT 17,4 PKT 0,58%

6.173,1 PKT 32,1 PKT 0,52%

Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.CVS Health and Danaher are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that CVS is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.CVS currently has a forward P/E ratio of 11.14, while DHR has a forward P/E of 26.17. We also note that CVS has a PEG ratio of 0.98. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DHR currently has a PEG ratio of 2.83.Another notable valuation metric for CVS is its P/B ratio of 1.12. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, DHR has a P/B of 2.84.These metrics, and several others, help CVS earn a Value grade of A, while DHR has been given a Value grade of D.CVS sticks out from DHR in both our Zacks Rank and Style Scores models, so value investors will likely feel that CVS is the better option right now.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: CVS Health und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf CVS Health

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf CVS Health

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu CVS Health Corp

Wer­bung

Analysen zu CVS Health Corp

DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
26.10.2018CVS Health Peer PerformWolfe Research
DatumRatingAnalyst
05.06.2019CVS Health BuyStandpoint Research
12.04.2019CVS Health Market PerformBMO Capital Markets
18.12.2018CVS Health OverweightBarclays Capital
30.01.2018CVS Health Strong BuyNeedham & Company, LLC
02.01.2018CVS Health BuyNeedham & Company, LLC
DatumRatingAnalyst
15.04.2019CVS Health PerformOppenheimer & Co. Inc.
26.10.2018CVS Health Peer PerformWolfe Research
28.06.2017CVS Health HoldNeedham & Company, LLC
02.02.2017CVS Health NeutralRobert W. Baird & Co. Incorporated
22.06.2016CVS Health HoldDeutsche Bank AG
DatumRatingAnalyst
25.07.2005Update Longs Drug Stores Corp.: UnderperformBear Stearns

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für CVS Health Corp nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen